Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Akero Therapeutics, retaining the price target of $80.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rami Katkhuda’s rating is based on Akero Therapeutics’ strong financial position and promising clinical developments. The company reported a robust cash reserve of $1.086 billion, which is projected to sustain operations until 2028. This financial stability provides a solid foundation for Akero’s ongoing and future clinical programs.
Additionally, Akero’s SYNCHRONY program, which involves the FGF21 analog efruxifermin (EFX), is progressing well. The upcoming preliminary data from the SYNCHRONY Real-World study, expected in the first half of 2026, will further validate the safety and efficacy of EFX. Moreover, the discontinuation of a competitor’s development in the same therapeutic area positions Akero favorably, as EFX has demonstrated significant anti-fibrotic activity. These factors collectively support the Buy rating for Akero Therapeutics.
In another report released on August 8, TD Cowen also maintained a Buy rating on the stock with a $76.00 price target.